Registry study for adults with AML and collected samples
Part of Blood & lymphatic, Cancer clinical trials.
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML (including a subtype called acute promyelocytic leukemia)
- You are 18 years or older
- You can sign a written informed consent form
- There are no other stated exclusion reasons for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a research registry that collects information and lab/blood sample data to better understand what acute leukemia looks like biologically and how patients do over time. It may help future treatment decisions, but it does not describe testing a new drug.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
This study collects health information from young people with a type of blood cancer called acute myeloid leukemia (AML). The goal is to learn more about the disease and improve future treatments. If you are under 25 and being treated for AML at a hospital in France, you might be able to join.
This study keeps a patient registry to collect information about people with specific myeloid blood neoplasms (a type of blood cancer). It helps researchers understand these conditions over time and may improve how patients are cared for in the future.
This is a registry (a study that collects health information over time) for adults with suspected or confirmed blood cancers of the myeloid type. It aims to better understand the biology of these illnesses and how different factors affect outcomes, which may improve care in the future.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.